Publications by authors named "R V Rawson"
Article Synopsis
- - Tumoral melanosis (TM) is characterized by clusters of melanin-filled macrophages in tissues, commonly linked to regressed melanoma, and is increasingly recognized due to advancements in melanoma treatments.
- - A study from 2006 to 2018 examined TM cases at a single institution, finding 79 patients with TM, predominantly in older males and often localized to the skin or lower limb, highlighting a strong correlation with melanoma cases.
- - Results indicated that patients with TM showed improved melanoma-specific survival compared to non-TM cases, particularly those without prior treatment, although no significant differences were found in recurrence-free survival.
Introduction: Overdose deaths from high-potency synthetic opioids, including fentanyl and its analogs, continue to rise along with emergency department (ED) visits for complications of opioid use disorder (OUD). Fentanyl accumulates in adipose tissue; although rare, this increases the risk of precipitated withdrawal in patients upon buprenorphine initiation. Many EDs have implemented medication for opioid use disorder (MOUD) programs using buprenorphine.
View Article and Find Full Text PDFCalifornia's Recovery Incentives Program: Implementation strategies.
J Subst Use Addict Treat
December 2024
Article Synopsis
- The increasing issue of stimulant use disorder (StimUD) in the US, particularly related to psychostimulants, has prompted California to implement a large-scale treatment initiative called the Recovery Incentives Program, utilizing contingency management (CM).
- The program employs the Science to Service Lab (SSL) approach, which includes training, feedback, and facilitation, enhanced with additional readiness assessments and ongoing monitoring of implementation fidelity.
- Initial findings suggest that the program is well-received by both treatment staff and participants, with plans for further evaluations to assess member progress and the ongoing effectiveness of the training and implementation strategies.
Article Synopsis
- In a study comparing neoadjuvant (before surgery) and adjuvant (after surgery) immunotherapy for stage III melanoma, neoadjuvant treatment showed greater effectiveness.
- The trial involved random assignment of 423 patients to receive either two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery, or surgery followed by 12 cycles of adjuvant nivolumab.
- Results indicated a significantly higher 12-month event-free survival rate in the neoadjuvant group (83.7%) compared to the adjuvant group (57.2%), with neoadjuvant therapy leading to better patient outcomes and more major pathological responses despite a higher incidence of severe adverse events.